Cargando…

Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection

Shengjiang Xiexin Decoction (SXD) is a widely recognized formula in Traditional Chinese Medicine (TCM) for treating diarrhea and is commonly used in clinical practice. Clostridium difficile infection (CDI) is a type of antibiotic-associated diarrhea with a rising incidence rate that has severe conse...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yutao, Zhang, Congen, Zhang, Xueqiang, Yu, Xiaohong, Ma, Yuqin, Qin, Xuemei, Ma, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189181/
https://www.ncbi.nlm.nih.gov/pubmed/37206044
http://dx.doi.org/10.1016/j.heliyon.2023.e15602
_version_ 1785043030209724416
author Cui, Yutao
Zhang, Congen
Zhang, Xueqiang
Yu, Xiaohong
Ma, Yuqin
Qin, Xuemei
Ma, Zhijie
author_facet Cui, Yutao
Zhang, Congen
Zhang, Xueqiang
Yu, Xiaohong
Ma, Yuqin
Qin, Xuemei
Ma, Zhijie
author_sort Cui, Yutao
collection PubMed
description Shengjiang Xiexin Decoction (SXD) is a widely recognized formula in Traditional Chinese Medicine (TCM) for treating diarrhea and is commonly used in clinical practice. Clostridium difficile infection (CDI) is a type of antibiotic-associated diarrhea with a rising incidence rate that has severe consequences for humans. Recent clinical applications have found significant efficacy in using SXD as an adjunct to CDI treatment. However, the pharmacodynamic substance basis and therapeutic mechanism of SXD remain unclear. This study aimed to systematically analyze the metabolic mechanisms and key pharmacodynamic components of SXD in CDI mice by combining non-targeted metabolomics of Chinese medicine and serum medicinal chemistry. We established a CDI mouse model to observe the therapeutic effect of SXD on CDI. We investigated the mechanism of action and active substance composition of SXD against CDI by analyzing 16S rDNA gut microbiota, untargeted serum metabolomics, and serum pharmacochemistry. We also constructed a multi-scale, multifactorial network for overall visualization and analysis. Our results showed that SXD significantly reduced fecal toxin levels and attenuated colonic injury in CDI model mice. Additionally, SXD partially restored CDI-induced gut microbiota composition. Non-targeted serum metabolomics studies showed that SXD not only regulated Taurine and hypotaurine metabolism but also metabolic energy and amino acid pathways such as Ascorbate and aldarate metabolism, Glycerolipid metabolism, Pentose and glucuronate interconversions, as well as body and other metabolite production in the host. Through the implementation of network analysis methodologies, we have discerned that Panaxadiol, Methoxylutcolin, Ginsenoside-Rf, Suffruticoside A, and 10 other components serve as critical potential pharmacodynamic substance bases of SXD for CDI. This study reveals the metabolic mechanism and active substance components of SXD for the treatment of CDI mice using phenotypic information, gut microbiome, herbal metabolomics, and serum pharmacochemistry. It provides a theoretical basis for SXD quality control studies.
format Online
Article
Text
id pubmed-10189181
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101891812023-05-18 Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection Cui, Yutao Zhang, Congen Zhang, Xueqiang Yu, Xiaohong Ma, Yuqin Qin, Xuemei Ma, Zhijie Heliyon Research Article Shengjiang Xiexin Decoction (SXD) is a widely recognized formula in Traditional Chinese Medicine (TCM) for treating diarrhea and is commonly used in clinical practice. Clostridium difficile infection (CDI) is a type of antibiotic-associated diarrhea with a rising incidence rate that has severe consequences for humans. Recent clinical applications have found significant efficacy in using SXD as an adjunct to CDI treatment. However, the pharmacodynamic substance basis and therapeutic mechanism of SXD remain unclear. This study aimed to systematically analyze the metabolic mechanisms and key pharmacodynamic components of SXD in CDI mice by combining non-targeted metabolomics of Chinese medicine and serum medicinal chemistry. We established a CDI mouse model to observe the therapeutic effect of SXD on CDI. We investigated the mechanism of action and active substance composition of SXD against CDI by analyzing 16S rDNA gut microbiota, untargeted serum metabolomics, and serum pharmacochemistry. We also constructed a multi-scale, multifactorial network for overall visualization and analysis. Our results showed that SXD significantly reduced fecal toxin levels and attenuated colonic injury in CDI model mice. Additionally, SXD partially restored CDI-induced gut microbiota composition. Non-targeted serum metabolomics studies showed that SXD not only regulated Taurine and hypotaurine metabolism but also metabolic energy and amino acid pathways such as Ascorbate and aldarate metabolism, Glycerolipid metabolism, Pentose and glucuronate interconversions, as well as body and other metabolite production in the host. Through the implementation of network analysis methodologies, we have discerned that Panaxadiol, Methoxylutcolin, Ginsenoside-Rf, Suffruticoside A, and 10 other components serve as critical potential pharmacodynamic substance bases of SXD for CDI. This study reveals the metabolic mechanism and active substance components of SXD for the treatment of CDI mice using phenotypic information, gut microbiome, herbal metabolomics, and serum pharmacochemistry. It provides a theoretical basis for SXD quality control studies. Elsevier 2023-04-20 /pmc/articles/PMC10189181/ /pubmed/37206044 http://dx.doi.org/10.1016/j.heliyon.2023.e15602 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Cui, Yutao
Zhang, Congen
Zhang, Xueqiang
Yu, Xiaohong
Ma, Yuqin
Qin, Xuemei
Ma, Zhijie
Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection
title Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection
title_full Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection
title_fullStr Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection
title_full_unstemmed Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection
title_short Integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of Shengjiang Xiexin decoction in the treatment of Clostridium difficile infection
title_sort integrated serum pharmacochemistry and metabolomics reveal potential effective components and mechanisms of shengjiang xiexin decoction in the treatment of clostridium difficile infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189181/
https://www.ncbi.nlm.nih.gov/pubmed/37206044
http://dx.doi.org/10.1016/j.heliyon.2023.e15602
work_keys_str_mv AT cuiyutao integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection
AT zhangcongen integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection
AT zhangxueqiang integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection
AT yuxiaohong integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection
AT mayuqin integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection
AT qinxuemei integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection
AT mazhijie integratedserumpharmacochemistryandmetabolomicsrevealpotentialeffectivecomponentsandmechanismsofshengjiangxiexindecoctioninthetreatmentofclostridiumdifficileinfection